About refractory GERD
Gastroesophageal reflux disease (GERD) is an uncomfortable condition in which acid from the stomach enters the esophagus, causing discomfort and, over time, damage to the esophagus. Refractory GERD is a condition in which standard acid reflux medications do not or no longer relieve GERD symptoms.
Proton pump inhibitors (PPIs) are a common type of medicine that alleviate symptoms in many patients with GERD. But people with refractory GERD continue to have symptoms even after treatment with PPIs. These symptoms often include chronic heartburn, a burning sensation under the breastbone, and regurgitation.
Refractory GERD is a serious condition that can be treated effectively. If left untreated, it can lead to a damaged esophagus.
Treat refractory GERD with Metozolv ODT
Metozolv ODT can treat refractory GERD1 and alleviate symptoms by helping to increase pressure on the valve that separates the esophagus and the stomach, keeping acid out of the esophagus. It also helps empty the stomach.
If your refractory GERD is currently being treated with metoclopramide or your current GERD treatment is not alleviating symptoms, talk with your healthcare professional about the benefits of Metozolv ODT.
Common symptoms of refractory GERD
Learn how Metozolv ODT treats refractory GERD
Learn more about Metozolv ODT
Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.